Clinical Trial Update: Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) [Phase 3]

View source ↗

Summary

A Phase 3 study is evaluating lenacapavir as a once-yearly injectable HIV pre-exposure prophylaxis (PrEP) and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lenacapavir (lenacapavir)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV Pre-exposure Prophylaxis | Phase 3 | Status: RECRUITING